April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Comparison of 2 Doses of Primary Intravitreal Bevacizumab for Subfoveal CNV in AMD at 24 Months: Results From the Pan-American Collaborative Retina Study Group
J. F. Arevalo; J. G. Sanchez; L. Wu; M. H. Berrocal; A. A. Alezzandrini; N. Restrepo; M. Maia; M. E. Farah; M. Díaz-Llopis; Pan-American Collaborative Retina Study Group
Author Affiliations & Notes
  • J. F. Arevalo
    Retina and Vitreous, Clinica Oftal Centro Caracas, Caracas, Venezuela
  • J. G. Sanchez
    Retina and Vitreous, Instituto Nacional de Investigación en Oftalmología (INIO), Medellin, Colombia
  • L. Wu
    Retina and Vitreous, Instituto de Cirugia Ocular, San Jose, Costa Rica
  • M. H. Berrocal
    Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico
  • A. A. Alezzandrini
    Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina
  • N. Restrepo
    Retina and Vitreous, Instituto Nacional de Investigación en Oftalmología (INIO), Medellin, Colombia
  • M. Maia
    Departamento de Oftalmologia - Instituto da Visão, The Universidade Federal de São Paulo, São Paulo, Brazil
  • M. E. Farah
    Departamento de Oftalmologia - Instituto da Visão, The Universidade Federal de São Paulo, São Paulo, Brazil
  • M. Díaz-Llopis
    Ophthalmology, Hospital La Fe, General Universitario de Valencia, Valencia, Spain
  • Pan-American Collaborative Retina Study Group
    Retina and Vitreous, Clinica Oftal Centro Caracas, Caracas, Venezuela
  • Footnotes
    Commercial Relationships  J.F. Arevalo, None; J.G. Sanchez, None; L. Wu, None; M.H. Berrocal, None; A.A. Alezzandrini, None; N. Restrepo, None; M. Maia, None; M.E. Farah, None; M. Díaz-Llopis, None.
  • Footnotes
    Support  The Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1250. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Comparison of 2 Doses of Primary Intravitreal Bevacizumab for Subfoveal CNV in AMD at 24 Months: Results From the Pan-American Collaborative Retina Study Group
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J. F. Arevalo, J. G. Sanchez, L. Wu, M. H. Berrocal, A. A. Alezzandrini, N. Restrepo, M. Maia, M. E. Farah, M. Díaz-Llopis, Pan-American Collaborative Retina Study Group; Comparison of 2 Doses of Primary Intravitreal Bevacizumab for Subfoveal CNV in AMD at 24 Months: Results From the Pan-American Collaborative Retina Study Group. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1250.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To report the 24-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) (1.25 mg or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods: : Retrospective multicenter interventional comparative case series. We reviewed the clinical records of 180 consecutive patients (207 eyes) with subfoveal CNV secondary to AMD. Patients were treated with at least one intravitreal injection of 1.25 mg (124 eyes [59.9%]) or 2.5 mg (83 eyes [40.1%]) of bevacizumab. Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline, 1-, 3-, 6-, 12- and 24-month visits.

Results: : The mean age of our patients was 74.3 ± 7.5 years. The mean number of intravitreal bevacizumab (IVB) injections per eye was 5.1 (range: 1 to 24 injections). In the 1.25 mg group, baseline BCVA improved from 20/235, logarithm of the minimum angle of resolution (logMAR) 1.07 to 20/172, logMAR 0.92 at 24 months (P < 0.0001). Similar BCVA changes were observed in the 2.5 mg group. Central macular thickness (CMT) at baseline by OCT in the 1.25mg group had a mean of 308.4 ± 127.52 µm which was reduced to a mean of 269.35 ± 97.92 µm, 262.1 ± 94.81 µm, 264.03 ± 97.06 µm, 245.91 ± 89.52 µm, and 249.27 ± 89.14 µm at 1, 3, 6, 12, and 24 months, respectively (P < 0.0001). Similar changes were observed in the 2.5 mg group. In the 2.5 mg group, systemic complications included 2 (2.6%) cases of arterial hypertension, one (1.3%) stroke, and one (1.3%) death.

Conclusions: : Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in subfoveal CNV secondary to AMD at 24 months. Our results show no significant difference regarding BCVA between IVB at doses of 1.25 mg or 2.5 mg.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: outcomes/complications • neovascularization 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept